ADMA Biologics’ (ADMA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report published on Monday, Marketbeat.com reports. HC Wainwright currently has a $18.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Mizuho raised their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a buy rating in a report on Thursday, June 20th. Cantor Fitzgerald restated an overweight rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $15.50.

ADMA Biologics Stock Down 4.5 %

Shares of NASDAQ:ADMA opened at $16.37 on Monday. The company has a 50 day moving average price of $17.82 and a two-hundred day moving average price of $12.46. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The company has a market capitalization of $3.79 billion, a PE ratio of -818.50 and a beta of 0.62. ADMA Biologics has a 52 week low of $3.06 and a 52 week high of $21.13.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) EPS. Analysts forecast that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock valued at $8,224,121 in the last ninety days. 3.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $29,000. EntryPoint Capital LLC acquired a new position in ADMA Biologics during the first quarter worth approximately $31,000. CWM LLC raised its stake in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $93,000. Finally, Viewpoint Capital Management LLC lifted its position in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 2,416 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.